Leo Pharma psoriasis drug approved in Europe

Leo Pharma has announced its compound for the treatment of scalp psoriasis has been approved for use in Europe.

Following its acceptance in 16 European countries, Xamiol will be launched first in the UK during the fourth quarter of 2008.

The company said the compound has proven itself to be an efficient treatment for the chronic skin condition psoriasis occurring in the scalp.

Furthermore, market surveys have shown patients, dermatologists and doctors alike to have great expectations for the compound.

In clinical trials involving over 5,300 patients in Europe and the US, around eight out of ten patients found their condition under control by the end of the treatment.

Gitte P Aabo, chief executive officer of Leo Pharma, said: “The approval of Xamiol opens up for amazing opportunities for LEO Pharma and the tens of thousands of psoriasis patients that have requested an efficient drug for treatment of the serious and visible scalp psoriasis.”

She added the approvals of the drug marks a significant step taken by the firm to realising its goal of offering patients most complete and best psoriasis treatment available.

In April 2008, Leo Pharma announced its financial results for the 2007 fiscal year, reporting a pre-tax result of 2,901 million Danish kroner (305.8 million pounds).